Project R-10062

Restoring defective regulators: a step towards an autologous regulatory T cell-based therapy for multiple sclerosis (Research)

Worldwide, 2.5 million people, especially young adults, suffer from MS. Developing an effective treatment that decreases the need for life-long treatment, rehabilitation and other costs and services would reduce the socio-economic burden. The aim of this project is to develop a T cell-based therapy that provides long-term protection against further disease progression. Therefore, we investigate what goes wrong with the regulatory T cells in MS and identify the most important targets involved in this process. The long-term goal is to create a personalized T cell product, in which the identified abnormalities in the regulatory cells will be corrected via gene therapy.

01 January 2020 - 31 March 2022